Reviews reflect personal experiences and are not medical advice. Always consult your doctor.
Manufacturer
Bristol-Myers Squibb / Pfizer EEIG
ATC Code
B01AF02
Source
EMA · EMEA/H/C/002148
(
ARTG
)
ELIQUIS is indicated for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip or total knee replacement surgery.,ELIQUIS is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke.,ELIQUIS is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adult patients.,ELIQUIS is indicated for the prevention of recurrent DVT and PE in adult patients.
⚠️ Warnings
• Caution should be exercised in patients with history of kidney or liver problems, bleeding problems, any allergy, who are taking other medications, children, during pregnancy and breastfeeding.
• Patients already taking 2.5 mg BID, avoid coadministration with strong dual inhibitors.
• Discontinuing eliquis in patients without adequate continuous anticoagulation increases risk of stroke.
